Loading
A phase 1/2 trial of Nivolumab in advanced solid tumours, run by Bristol-Myers Squibb, active and no longer recruiting.
A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05888831 by Bristol-Myers Squibb, with 100 participants enrolled, started 2023-06-06 and due to reach its primary completion in 2026-09-30. Interventions recorded: BMS-986449 and Nivolumab.
Shares Bristol Myers Squibb, Nivolumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Bristol Myers Squibb, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Bristol Myers Squibb, Nivolumab, Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Nivolumab, Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Nivolumab, Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Nivolumab, Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Bristol Myers Squibb, Nivolumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Nivolumab, Immune checkpoint inhibitors and the tag pipeline.